Literature DB >> 15746744

Polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia is equivalent to hypothermic potassium blood cardioplegia.

Joel S Corvera1, Hajime Kin, Geoffrey P Dobson, Faraz Kerendi, Michael E Halkos, Sara Katzmark, Christopher S Payne, Zhi-Qing Zhao, Robert A Guyton, Jakob Vinten-Johansen.   

Abstract

BACKGROUND: Hypothermic depolarizing hyperkalemic (K + 20 mEq/L) blood cardioplegia is the "gold standard" in cardiac surgery. K + has been associated with deleterious consequences, eg, intracellular calcium overload. This study tested the hypothesis that elective arrest in a polarized state with adenosine (400 micromol/L via adenosine triphosphate-sensitive potassium channel opening) and the Na + channel blocker lidocaine (750 micromol/L) as the arresting agents in blood cardioplegia provides cardioprotection comparable to standard hypothermic K + -blood cardioplegia.
METHODS: Anesthetized dogs were placed on cardiopulmonary bypass and assigned to 1 of 3 groups receiving antegrade cardioplegia delivered every 20 minutes for 1 hour of arrest: cold (10 degrees C) K + -blood cardioplegia (n = 6), cold (10 degrees C) adenosine/lidocaine blood cardioplegia (n = 6), or warm (37 degrees C) adenosine/lidocaine blood cardioplegia (n = 6). After an hour of arrest, cardiopulmonary bypass was discontinued, and reperfusion was continued for 120 minutes.
RESULTS: Time to arrest was longer with cold and warm adenosine/lidocaine blood cardioplegia (175 +/- 19 seconds and 143 +/- 19 seconds, respectively) compared with K + -blood cardioplegia (27 +/- 2 seconds; P < .001). Postcardioplegia left ventricular systolic function (slope of the end-systolic pressure/dimension relationship) was comparable among the 3 groups (K + -blood cardioplegia, 15.2 +/- 2.1 mm Hg/mm; cold adenosine/lidocaine blood cardioplegia, 15.9 +/- 3.4 mm Hg/mm; warm adenosine/lidocaine blood cardioplegia, 14.1 +/- 2.8 mm Hg/mm; P = .90). Plasma creatine kinase activity in cold and warm adenosine/lidocaine blood cardioplegia was similar to that in K + -blood cardioplegia at 120 minutes of reperfusion (cold adenosine/lidocaine blood cardioplegia, 11.5 +/- 2.1 IU/g protein; warm adenosine/lidocaine blood cardioplegia, 10.1 +/- 0.9 IU/g protein; K + -blood cardioplegia, 7.6 +/- 0.8 IU/g protein; P = .17). Postcardioplegia coronary artery endothelial function was preserved in all groups.
CONCLUSIONS: Intermittent polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia provided the same degree of myocardial protection as intermittent hypothermic K + -blood cardioplegia in normal hearts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15746744     DOI: 10.1016/j.jtcvs.2004.07.021

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.

Authors:  Hiroshi Yamamoto; Fumio Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-07-23

2.  Organ protective mechanisms common to extremes of physiology: a window through hibernation biology.

Authors:  Quintin J Quinones; Qing Ma; Zhiquan Zhang; Brian M Barnes; Mihai V Podgoreanu
Journal:  Integr Comp Biol       Date:  2014-05-21       Impact factor: 3.326

3.  Excellent outcomes in a case of complex re-do surgery requiring prolonged cardioplegia using a new cardioprotective approach: adenocaine.

Authors:  James J O'Rullian; Stephen E Clayson; Raul Peragallo
Journal:  J Extra Corpor Technol       Date:  2008-09

Review 4.  Hyperkalemic cardioplegia for adult and pediatric surgery: end of an era?

Authors:  Geoffrey P Dobson; Giuseppe Faggian; Francesco Onorati; Jakob Vinten-Johansen
Journal:  Front Physiol       Date:  2013-08-28       Impact factor: 4.566

5.  A novel survival model of cardioplegic arrest and cardiopulmonary bypass in rats: a methodology paper.

Authors:  Fellery de Lange; Kenji Yoshitani; Mihai V Podgoreanu; Hilary P Grocott; G Burkhard Mackensen
Journal:  J Cardiothorac Surg       Date:  2008-08-19       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.